JFG
CRSP icon

Jefferies Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Jefferies Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60,000
Closed -$3.15M – 1823
2025
Q4 		$3.15M Hold
60,000
– – 0.02% 630
2025
Q3 		$3.89M Buy
+60,000
New +$3.44M 0.02% 442
2024
Q1 		– Sell
-25,000
Closed -$1.56M – 1677
2023
Q4 		$1.56M Buy
+25,000
New +$1.38M 0.01% 800
2023
Q1 		– Sell
-15,000
Closed -$610K – 1683
2022
Q4 		$610K Buy
+15,000
New +$796K ﹤0.01% 1006

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jefferies Financial Group's CRSP Position: Q1 2024 in Review

Jefferies Financial Group sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 1 share — an estimated $63 sold.

Jefferies Financial Group first reported a position in CRSP in Q4 2022 and held it in 2 quarters. The position peaked at $174K in Q4 2022. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Jefferies Financial Group reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 1 CRISPR Therapeutics share in Q1 2024, an estimated $63.
  • Jefferies Financial Group first reported a position in CRISPR Therapeutics in Q4 2022 and held it in 2 quarters.
  • Jefferies Financial Group's CRISPR Therapeutics position peaked at $174K in Q4 2022.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Jefferies Financial Group's 13F filing for Q1 2024, filed 13 May 2024.